Renaissance Technologies’s DarioHealth DRIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-6,490
Closed -$87K 3589
2025
Q2
$87K Buy
6,490
+610
+10% +$8.46K ﹤0.01% 3323
2025
Q1
$72K Buy
5,880
+1,295
+28% +$18.3K ﹤0.01% 3237
2024
Q4
$72.1K Buy
4,585
+200
+5% +$3.46K ﹤0.01% 3334
2024
Q3
$98.2K Sell
4,385
-200
-4% -$4.05K ﹤0.01% 3260
2024
Q2
$109K Sell
4,585
-175
-4% -$4.96K ﹤0.01% 3167
2024
Q1
$146K Buy
4,760
+360
+8% +$13.7K ﹤0.01% 3294
2023
Q4
$151K Buy
4,400
+545
+14% +$19.4K ﹤0.01% 3213
2023
Q3
$253K Buy
3,855
+605
+19% +$40.8K ﹤0.01% 3006
2023
Q2
$261K Buy
3,250
+358
+12% +$27.2K ﹤0.01% 3187
2023
Q1
$238K Buy
2,892
+2,002
+225% +$197K ﹤0.01% 3209
2022
Q4
$76K Buy
+890
New +$80.1K ﹤0.01% 3698
2022
Q3
Sell
-4,810
Closed -$591K 4090
2022
Q2
$591K Buy
4,810
+1,755
+57% +$206K ﹤0.01% 3054
2022
Q1
$357K Buy
+3,055
New +$505K ﹤0.01% 3388
2021
Q1
Sell
-1,915
Closed -$547K 3396
2020
Q4
$547K Buy
+1,915
New +$494K ﹤0.01% 2783
2020
Q3
Sell
-855
Closed -$109K 3437
2020
Q2
$109K Buy
+855
New +$114K ﹤0.01% 3263

Other funds holding DRIO

Renaissance Technologies's DRIO Position: Q3 2025 in Review

Renaissance Technologies sold out of DarioHealth (DRIO) in Q3 2025, closing a stake of 6,490 shares — an estimated $87K sold.

Renaissance Technologies first reported a position in DRIO in Q2 2020 and held it in 15 quarters. The position peaked at $591K in Q2 2022. 23 funds tracked by Wall St. Rank hold DRIO as of Q3 2025.

  • Renaissance Technologies reported no remaining DarioHealth position as of Q3 2025 after selling out during the quarter.
  • Renaissance Technologies sold 6,490 DarioHealth shares in Q3 2025, an estimated $87K.
  • Renaissance Technologies first reported a position in DarioHealth in Q2 2020 and held it in 15 quarters.
  • Renaissance Technologies's DarioHealth position peaked at $591K in Q2 2022.
  • 23 funds tracked by Wall St. Rank held DarioHealth as of Q3 2025.

Based on Renaissance Technologies's 13F filing for Q3 2025, filed 13 Nov 2025.